DUBLIN--(BUSINESS WIRE)--The "NIASPAN Drug Profile, 2019" report has been added to ResearchAndMarkets.com's offering.
NIASPAN Drug Profile, 2019 is part of a deep library of business intelligence on biopharmaceutical drugs. The report focuses on NIASPAN and covers the following critical aspects of this drug:
- United States patents
- Expired United States patents
- District Court patent litigation
- Clinical trials
- Drug prices
- Annual sales revenues
- Finished product suppliers
- Raw active pharmaceutical ingredient (API) sources
Topics Covered
- Profile for NIASPAN
- US Patents
- Expired US Patents
- US District Court Litigation
- International (ex US) Patents
- Clinical Trials
- Drug Prices - Average Pharmacy Cost
- Annual Sales Revenues
- Finished Product Suppliers
- Bulk API Sources
Companies Featured
- Abbvie
- Rebel Distributors Corp
- A-S Medication Solutions
- Carilion Materials Management
- Dispensing Solutions Inc.
- Zydus Pharmaceuticals USA Inc
- Chemexper Chemical Directory
- Sigma-Aldrich
- Specs
- Novoseek
- Vitas-M Laboratory
- Mp Biomedicals
- Emd Biosciences
- Molport
- Nih Clinical Collection
- Abi Chem
- Finetech Industry Limited
- Chembase.Cn
- Nanjing Kaimubo
- Ak Scientific Inc. (Aksci)
- Alsachim
- Debye Scientific Co. Ltd
- Molepedia
- Boc Sciences
- Oxchem Corporation
- Zinc
- Alfa Aesar
- Molmall
- Ambinter
- Combi-Blocks
- Aa Blocks
- 001Chemical
- Ambeed
- Acros Organics
-
and many more...
For more information about this report visit https://www.researchandmarkets.com/research/mqgm5f/niaspan_drug?w=4
